Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease

On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B‐cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab was authorized to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Ali, Sahra, Moreau, Alexandre, Melchiorri, Daniela, Camarero, Jorge, Josephson, Filip, Olimpier, Odoardo, Bergh, Jonas, Karres, Dominik, Tzogani, Kyriaki, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Regulatory Issues: EMA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160312/
https://ncbi.nlm.nih.gov/pubmed/32297447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados